Leslie L. Popplewell, M.D.
Board Certification, Internal Medicine
Board Certification, Hematology
M.D., F.A.C.P.
1988 - 1992, University of Louisville School of Medicine, Louisville, Kentucky, M.D., Internal Medicine
1984 - 1988, University of Kentucky, Lexington, Kentucky, B.S., Biology
1998 - 2000, Fellowship, Bone Marrow Transplantation, City of Hope, Duarte, CA
1995 - 1998, Fellowship, Medical Oncology and Hematology, Memorial Sloan-Kettering Cancer Center, New York, NY
1992 -1995, Residency, Internal Medicine, Temple University Hospital, Philadelphia, Pennsylvania
2020-present, Chief, Division of Lymphoma, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2018-Present, Co-Director, The Judy and Bernard Briskin Center for Clinical Research, City of Hope, Duarte, CA
2010-Present, Associate Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2000-2010, Assistant Clinical Professor, Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
2006 - 2007, Recipient, Tim Nesvig Lymphoma Fellowship Award
2000, Recipient, Lymphoma Research Foundation Association Research Grant
1999 - 2000, Recipient, Amgen Oncology Fellow Award
1997, Recipient, Merit Award, American Society of Clinical Oncology
1997, Board Eligible, Oncology and Hematology
1996 - 1997, Chief Fellow, Memorial Sloan Kettering Cancer Center
1996 - 1997, Recipient, Mortimer Lacher Fellowship
1996, Recipient, Merit Award, American Society of Hematology
1995, Recipient - Louis J. Treton Award - Most Outstanding 3rd Year Resident
- CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin's lymphoma
R Advani, I Flinn, L Popplewell, A Forero… - … England Journal of …, 2018 - Mass Medical Soc Abstract Background The Hu5F9-G4 (hereafter, 5F9) antibody is a macrophage immune checkpoint inhibitor blocking CD47 that induces tumor-cell phagocytosis. 5F9 synergizes with rituximab to eliminate B-cell non-Hodgkin's lymphoma cells by enhancing macrophage … - Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study
…, L Pinter-Brown, N Bartlett, L Popplewell… - Journal of clinical …, 2011 - ncbi.nlm.nih.gov From the New York University (NYU) Cancer Institute, NYU Langone Medical Center; New York Weill Cornell Medical Center; Memorial Sloan-Kettering Cancer Center, New York, NY; University of Texas MD Anderson Cancer Center, Houston, TX; University of California at Los Angeles …Cited by 547 Related articles All 17 versions - First-in-human study of utomilumab, a 4-1BB/CD137 agonist, in combination with rituximab in patients with follicular and other CD20+ non-Hodgkin lymphomas
AK Gopal, R Levy, R Houot, SP Patel, L Popplewell… - Clinical Cancer …, 2020 - AACR Purpose: In this phase I study (NCT01307267), we evaluated safety, pharmacokinetics, clinical activity, and pharmacodynamics of treatment with utomilumab plus rituximab in patients with relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin … Cited by 9 Related articles All 6 versions - Double-hit signature with TP53 abnormalities predicts poor survival in patients with germinal center type diffuse large B-cell lymphoma treated with R-CHOP
…, R Pillai, J Wang, X Wu, J Zain, L Popplewell… - Clinical Cancer …, 2021 - AACR Purpose: We performed detailed genomic analysis on 87 cases of de novo diffuse large B-cell lymphoma of germinal center type (GCB DLBCL) to identify characteristics that are associated with survival in those treated with R-CHOP (rituximab, cyclophosphamide …Cited by 1 Related articles All 3 versions - CALGB 50604: risk-adapted treatment of nonbulky early-stage Hodgkin lymphoma based on interim PET
…, ED Hsi, H Schöder, LL Popplewell… - Blood, The Journal …, 2018 - ashpublications.org A negative interim positron emission tomography/computerized tomography (PET/CT) after 1 to 3 cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients with newly diagnosed, nonbulky stage I or II Hodgkin lymphoma (HL) predicts a low relapse rate … Cited by 41 Related articles All 10 versions - CD19-targeting CAR-T cell therapy in CNS lymphoma
T Siddiqi, X Wang, J Palmer, LL Popplewell… - 2019 - ashpublications.org Background: Prognosis is generally poor for patients (pts) with primary or secondary central nervous system (CNS) lymphoma. We report data from such patients treated on the ongoing